Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer

(2013) Arjun V. Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer

(2012) Matthew D. Galsky et al.   Clinical Genitourinary Cancer

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

(2012) G. M. Blumenthal et al.   ONCOLOGIST

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

(2011) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis

(2011) E. M. Battinelli et al.   BLOOD

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

(2011) F. A. Yafi et al.   Current Oncology

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75

(2011) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

(2008) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS